Amyotrophic Lateral Sclerosis and Muscle Relaxants
Depolarizing muscle relaxants (succinylcholine/suxamethonium) should be absolutely avoided in patients with ALS due to the risk of life-threatening hyperkalemia from denervated muscle. Use non-depolarizing agents instead, with careful dose reduction and mandatory neuromuscular monitoring.
Depolarizing Agents: Contraindicated
Patients with ALS have denervated, hypersensitive muscle tissue that expresses extrajunctional acetylcholine receptors throughout the muscle membrane. When exposed to depolarizing agents like succinylcholine, this causes:
- Massive potassium release from muscle cells
- Potentially fatal hyperkalemic cardiac arrest
- Risk similar to other denervation states (burns, spinal cord injury)
This is a hard contraindication 1. The mechanism is well-established in neuromuscular disease states, and the mortality risk is unacceptable.
Non-Depolarizing Agents: Recommended with Caution
Agent Selection
Rocuronium is the preferred non-depolarizing agent because it can be reliably reversed with sugammadex, though significant caveats exist (see below) 2.
Alternative agents include:
- Atracurium
- Cisatracurium
- Vecuronium
Critical Dosing Principles
Reduce initial doses by 50-75% compared to standard dosing due to markedly increased sensitivity in ALS patients. ALS patients demonstrate:
- Heightened sensitivity to non-depolarizing agents
- Prolonged duration of action
- Risk of incomplete reversal even with standard reversal doses
Start with test doses: For rocuronium, consider 0.3-0.4 mg/kg (vs. standard 0.6 mg/kg) or even lower (0.52 mg/kg successfully used in case reports) 3, 4.
Mandatory Neuromuscular Monitoring
Quantitative train-of-four (TOF) monitoring is absolutely essential - not optional - throughout the entire perioperative period 2:
- Monitor continuously from induction through full recovery
- Do not rely on clinical assessment alone
- Ensure TOF ratio ≥0.9 before extubation
- Continue monitoring post-reversal for recurarization
Reversal Strategy
For Rocuronium/Vecuronium: Sugammadex
Sugammadex is the preferred reversal agent for steroidal muscle relaxants in ALS patients, but with critical warnings 2:
Dosing based on depth of blockade:
- Very moderate block (TOF ratio 0.5): 0.22 mg/kg
- Moderate block (TOF count = 4): 1.0-2.0 mg/kg
- Deep block (TOF count = 2): 2.0-4.0 mg/kg
- Very deep block (PTC 1-2): 4.0 mg/kg
- Immediate reversal: 8.0 mg/kg
Critical Caveat: Incomplete Reversal Risk
Case reports document incomplete reversal and recurarization in ALS patients even with appropriate sugammadex dosing 5. In one case:
- 4 mg/kg sugammadex initially achieved TOF ratio 54%
- Patient then re-paralyzed (TOF count dropped to 1-3, tidal volume <100 mL)
- Required additional 50 mg sugammadex
- Delayed full recovery
This means:
- Standard sugammadex doses may be insufficient
- Have additional sugammadex immediately available
- Monitor for at least 30-60 minutes post-reversal
- Consider ICU admission for continued monitoring
- Do NOT extubate until TOF ratio definitively ≥0.9 and stable
For Atracurium/Cisatracurium: Neostigmine
If using benzylisoquinolinium agents, reversal with neostigmine 2:
- Only reverse when TOF count = 4 (wait if fewer responses)
- Dose: 0.04 mg/kg neostigmine + 0.02 mg/kg atropine
- Expect 10-20 minutes to achieve TOF ratio ≥0.9
- Continue monitoring throughout recovery period
Alternative Approach: Avoid Muscle Relaxants Entirely
Consider deep inhalational anesthesia without muscle relaxants when feasible 6:
- High-dose propofol (3 mg/kg) + sevoflurane (5%) for intubation
- Maintain with 2-3% sevoflurane for surgical relaxation
- Eliminates reversal concerns entirely
- Suitable for shorter procedures where profound relaxation not essential
Postoperative Management
Plan for extended monitoring and respiratory support:
- ICU admission strongly recommended
- Assisted ventilation may be needed despite "adequate" reversal
- ALS patients have baseline respiratory compromise
- Risk of aspiration pneumonia is elevated (documented in case reports) 5
- Have non-invasive ventilation immediately available
Key Pitfalls to Avoid
- Never use succinylcholine - this cannot be overstated
- Never use standard muscle relaxant doses - always reduce significantly
- Never rely on clinical assessment alone - quantitative monitoring mandatory
- Never assume standard reversal doses are adequate - have extra sugammadex ready
- Never extubate without confirmed TOF ratio ≥0.9 - recurarization is documented
- Never discharge to floor - these patients need ICU-level monitoring
The evidence base consists primarily of case reports and expert consensus 3, 5, 4, 6, with general muscle relaxant guidelines 2 providing the reversal framework. The 2020 Anaesthesia guidelines provide the most comprehensive and recent guidance on reversal strategies, though they don't specifically address ALS populations.